EVENT

Follow @Boehringer on Twitter for the latest news from #ASCO15 and keep an eye on News Centre for our latest announcements.

ASCO 2015

Latest oncology news from Boehringer Ingelheim presented at the 2015 ASCO Annual Meeting*.
  • ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
  • In the Phase III LUX-Lung 8 trial, afatinib** significantly improved overall survival compared to erlotinib, reducing the risk of death by 19% in patients with advanced squamous cell carcinoma of the lung, previously treated with first-line chemotherapy
  • Afatinib significantly delayed progression of lung cancer (primary endpoint) and improved control of cancer-related cough and shortness of breath compared to erlotinib
  • The overall rate of severe adverse events (≥grade 3) was similar between both therapies, with differences observed in the incidence of certain side effects
  • Global regulatory submissions are planned later this year to treat this patient population

*Not an official event of the 2015 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or Conquer Cancer Foundation.
**Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF® for use in patients with distinct types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.

1.Soria JC, et al. Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). Abstract #8002 presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA. 29 May – 2 June 2015.
2.Goss GD, et al., A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). Abstract #1222O presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain. 26 – 30 September 2014.